Total neoadjuvant therapy for locally advanced rectal cancer A meaningful treatment option?

Article Oncology

Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial

Emmanouil Fokas et al.

Summary: This study reported the long-term results of total neoadjuvant therapy in locally advanced rectal cancer, showing that chemoradiotherapy followed by chemotherapy resulted in higher pathological complete response without compromising disease-free survival, toxicity, quality of life, or stool incontinence, and is proposed as the preferred sequence for total neoadjuvant therapy if organ preservation is a priority.

JAMA ONCOLOGY (2022)

Add to Collection

Article Oncology

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Renu R. Bahadoer et al.

Summary: The RAPIDO trial aimed to reduce systemic relapses in locally advanced rectal cancer through short-course radiotherapy, chemotherapy, and delayed surgery. Results showed a decreased probability of disease-related treatment failure in the experimental group compared to standard care, with diarrhea being the most common adverse event and neurological toxicity being prominent in the standard care group during adjuvant chemotherapy.

LANCET ONCOLOGY (2021)

Add to Collection

Review Oncology

Prognostic Importance of MRI-Detected Extramural Venous Invasion in Rectal Cancer: A Literature Review and Systematic Meta-Analysis

Jessica Juliana Tan et al.

Summary: mrEMVI is significantly associated with worsened survival outcomes in rectal cancer, both at baseline and after neoadjuvant treatment. Regression of mrEMVI after neoadjuvant treatment is associated with improved survival outcomes. Accurate and consistent reporting of mrEMVI status is essential.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

Add to Collection

Article Oncology

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23) : a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy et al.

Summary: In patients with cT3 or cT4 M0 rectal cancer, intensifying chemotherapy with FOLFIRINOX before preoperative chemoradiotherapy significantly improved disease-free survival outcomes and reduced neurotoxicity. Thus, the PRODIGE 23 results have the potential to impact clinical practice.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology